Sign In
Buy MRNA
$49.06
+3.42 (+7.49%)
At Close: Jun 03, 2026
Why Moderna Stock Just Popped
01:15pm, Wednesday, 18'th Feb 2026
The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind.
Stock Market Today: Stocks Rise as Tech Gains Ground Amid Easing AI Fears
11:48am, Wednesday, 18'th Feb 2026
The major stock indexes rose on Wednesday morning as the AI rally found its footing after a string of volatile sessions colored by concerns about AI-driven disruption.
Moderna's investigational flu vaccine moves forward in FDA review
11:23am, Wednesday, 18'th Feb 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meet
FDA agrees to review Moderna's mRNA flu vaccine application in a reversal
11:17am, Wednesday, 18'th Feb 2026
Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a decisi
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
11:00am, Wednesday, 18'th Feb 2026
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many o
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
10:22am, Wednesday, 18'th Feb 2026
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
Moderna Stock Pops as FDA Application Moves Forward
10:16am, Wednesday, 18'th Feb 2026
Pharma giant Moderna Inc (NASDAQ:MRNA) is enjoying a boost today, after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review.
FDA reverses decision not to review Moderna's new flu vaccine
09:35am, Wednesday, 18'th Feb 2026
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.
09:27am, Wednesday, 18'th Feb 2026
The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.
Stock Futures Rise as Economic Data Rolls In
09:22am, Wednesday, 18'th Feb 2026
Stock futures are higher as economic data rolls in ahead of today's Fed minutes
The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot
09:12am, Wednesday, 18'th Feb 2026
The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.
Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial
07:13am, Wednesday, 18'th Feb 2026
A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company
US FDA to initiate review of Moderna's influenza vaccine
07:07am, Wednesday, 18'th Feb 2026
Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received
Moderna’s investigational flu vaccine moves forward in FDA review
06:18am, Wednesday, 18'th Feb 2026
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza...
